Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
investing succesffuly to reach your goals investing succesffuly to reach your goals
X

Fredun Pharmaceuticals Ltd Stock Analysis

Small Cap
Evaluated by 79 users | BSE: 539730 | NSE: |
Pharmaceuticals & Drugs

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Capital Employed 6.4%5.66%7.81%18.88%9.42%15.7%9.48%10.5%15.02%7.25%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 811.715.121.325.342.356.759.697113
Y-o-Y Gr. Rt.-46.6%29.1%41.1%19%67.1%34%5%62.9%16.3%
Adjusted EPS (Rs.) -0.04-0.79-0.144.591.314.443.524.8711.524.36
Y-o-Y Gr. Rt.-NANANA-71.5%238.9%-20.7%38.4%136.6%-62.2%
Book Value per Share (Rs.) 11.2510.1310.0610.9711.515.6820.1464.7197.73103.57
Adjusted Net Profit 0-0.201.10.31.10.81.74.61.7
Net Op. Cash Flow (Rs. Cr.) 001.3-0.71.83.3417.30.8-10.6
Debt to Cash Flow from Ops 003.74-10.385.14.674.630.5723.05-3.28
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Fredun Pharmaceuticals Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales 34.3%34.8%25.8%16.3%
Adjusted EPS NA27.2%7.4%-62.2%
Book Value per Share 2855.272.66
Share Price - 84.6% 12.8% 120.7%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20
Return on Equity (%) -0.35-6.66-1.2139.3110.3829.6914.7711.3415.044.33
Operating Profit Margin (%) 9.482.787.3612.346.729.836.019.5910.547.38
Net Profit Margin (%) -0.13-1.6-0.215.071.222.471.462.84.741.54
Debt to Equity 1.411.831.842.493.063.922.530.450.490.84
Working Capital Days 180172175155167174200261230277
Cash Conversion Cycle 32251616182812-311592
Entity Percentage Holding
Promoters 52.04%
Institutions 1.88%
Non-Institutions 46.08%
Pledged *0.000.003.853.855.545.545.545.545.545.54
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

The 5-year analysis of Fredun Pharmaceuticals Ltd's performance infers:

Fredun Pharmaceuticals Ltd earnings have grown by 27.2%, whereas share price has appreciated 84.6% CAGR over the past five years, indicating the company's share price is likely overvalued. However, for specific investment actions please connect with your investment advisor.

Data is not available for this company

No data to display
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback